Wednesday, December 17, 2025 Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. This post hoc analysis used a clinically validated, tumor-informed assay to determine ctDNA status in 940 patients with stage III colon cancer and found that ctDNA negativity was highly associated with improved survival. Patients with ctDNA positivity demonstrated a survival benefit with adjuvant celecoxib, whereas patients with ctDNA negativity did not. Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O’Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA. Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial (ONLINE). JAMA Oncology 2025.https://doi.org/10.1001/jamaoncol.2025.5144
